Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 9/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 9/20 | 0.38 |
| ▸ | SCN8A | Q9UQD0 | 9/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.35 |
| ▸ | CA2 | P00918 | 4/20 | 0.35 |
| ▸ | CA9 | Q16790 | 4/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA3 | P07451 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | IGLV6-57 | P01721 | 1/20 | 0.32 |
| ▸ | LPL | P06858 | 2/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25706773 | 1.00 | SCN1A (0.38) | SCN1ASCN5ASCN8ACA1CA2 | |
| SCHEMBL31319010 | 0.85 | CYP19A1 (0.41) | CA1CA2CA9CA12CA3 | |
| SCHEMBL25706902 | 0.85 | CYP19A1 (0.41) | CA1CA2CA9CA12CA3 | |
| SCHEMBL24133485 | 0.84 | LPL (0.39) | CA1CA2CA9CA12CA3 | |
| SCHEMBL25313255 | 0.84 | LPL (0.39) | CA1CA2CA9CA12CA3 | |
| SCHEMBL25288246 | 0.84 | LPL (0.39) | CA1CA2CA9CA12CA3 | |
| SCHEMBL30408224 | 0.84 | LPL (0.39) | CA1CA2CA9CA12CA3 | |
| SCHEMBL25706906 | 0.82 | CA1 (0.35) | CA1CA2CA9CA12CA3 | |
| SCHEMBL31319099 | 0.82 | CA1 (0.35) | CA1CA2CA9CA12CA3 | |
| SCHEMBL31319039 | 0.81 | SLC6A4 (0.36) | SCN1ASCN5ASCN8ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-04-10 | — | — | US | disclosed |
| US-20250059188-A1 | ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | SCN1A 2518/4885SCN5A 3362/4885SCN8A 3450/4885 |
| US-20250059188-A1 | ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | SCN1A 1078/4885SCN5A 1874/4885SCN8A 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.